

## **Department of Public Safety and Correctional Services**

Office of the Secretary 300 E. JOPPA ROAD • SUITE 1000 • TOWSON, MARYLAND 21286-3020 (410) 339-5000 • FAX (410) 339-5071 • TOLL FREE (877) 379-8636 • V/TTY (800) 735-2258 • <u>www.dpscs.maryland.gov</u>

STATE OF MARYLAND

LARRY HOGAN GOVERNOR

BOYD K. RUTHERFORD LT. GOVERNOR

STEPHEN T. MOYER SECRETARY

WILLIAM G. STEWART DEPUTY SECRETARY ADMINISTRATION

J. MICHAEL ZEIGLER DEPUTY SECRETARY OPERATIONS

RHEA L. HARRIS ASSISTANT SECRETARY PROGRAMS AND SERVICES

DAVID N. BEZANSON ASSISTANT SECRETARY CAPITAL PROGRAMS Amendment #17 To Request For Proposals (RFP) Pharmacy Services Solicitation No. Q0016025 February 28, 2018

Ladies and Gentlemen:

This Addendum is being issued to amend and clarify certain information contained in the above named RFP. All information contained herein is binding on all Offerors who respond to this RFP. Specific parts of the RFP have been amended. The following changes/additions are listed below. New language for inclusion in the RFP has been underlined and marked in bold (ex. <u>new language</u>), and language deleted has been marked with a strikeout (ex. language deleted).

1. AMEND RFP Section 1.2.9 as follows:

**1.2.9 Clinical Liaison** – The Contractor shall designate one Clinical Doctor of Pharmacy (Pharm.D.) that has completed residency training, or has equivalent experience in direct patient care as defined by the American College of Clinical Pharmacy, to act as the Clinical Liaison to the CMO and who will be the designated co-chairperson for the Department's quarterly Statewide Pharmacy & Therapeutics Committee (P&T Committee) meetings. This Contractor Clinical Liaison is in addition to the five (5) Contractor Clinical Pharm.Ds required under RFP § 3.2.17 and will have the obligation to be responsive to any requests by the DPSCS CMO to attend other meetings as required and facilitate problem solving regarding medication utilization with other vendor statewide medical and mental health Directors as requested. The Clinical Liaison will also respond to any inquiries or concerns raised by the DPSCS Chief Nursing Officer. The Clinical Liaison shall have correctional experience as well as supervisional /managerial experience in order to provide guidance in the reporting of the pharmaceutical processes, cost saving, protocols/policy experience. National Board certification with clinical process experiences are preferred. Cost models development experience regarding HCV and HIV medications is also preferred.

2. AMEND RFP Section 1.2.16 as follows:

**1.2.16 Contractor Clinical Pharm.D.** – A clinical pharmacist, employed by the contractor, who holds a Pharm.D. degree with residency training completion, or has equivalent experience in direct patient care as defined by the American College of Clinical Pharmacy, and has in-depth knowledge of medications and consults with physicians and other health care professionals on drug dose control and drug usage. The Contractor Clinical

Pharm.D. is the primary point-of-contact for the CMO for clinical or non-administrative issues concerning the Contractor's performance under the Contract.

3. AMEND RFP Attachments D by replacing Revised Attachment D-1A – MBE Utilization and Fair Solicitation Affidavit & MBE Participation Schedule with 2nd Revised Attachment D-1A – MBE Utilization and Fair Solicitation Affidavit & MBE Participation Schedule.

4. AMEND the Key Information Summary Sheet as follows:

MBE Subcontracting Goal:	<u>    12 %</u>
MBE Subcontracting Goal:	7 %

5. AMEND RFP Section 1.33.1 as follows:

1.33.1 Establishment of Goal and Subgoals

An overall MBE subcontractor participation goal of  $\frac{12\%}{7\%}$  of the total value of the Annual Management Fee portion only (aggregate of the Annual Management Fee paid on entire contract as set forth in Attachment F), including all option years, if any, has been established for this procurement.

6. AMEND RFP Section 4.5 as follows:

Under separate sealed cover from the Technical Proposal and clearly identified in the format identified in Section 4.2 "Proposals," the Offeror shall submit an original unbound copy, two (2) copies, and an electronic version in Microsoft Word or Microsoft Excel of the Financial Proposal. The Financial Proposal shall contain all price information in the format specified in Attachment F.

With its financial proposal the Offeror shall submit a manufacturer's or retailers' invoice documenting the AAC paid for each of the Pharmaceuticals and Supplies on Attachment F. These invoices shall be organized in the same order as the listing on the Pharmaceuticals & Supplies Tab in Attachment F – Financial Proposal Form. One electronic copy and one hard copy of the invoices shall be provided with the Financial Proposal.

The Offeror shall submit an invoice for each unit price identified on the Attachment F. The Offeror shall complete the Financial Proposal Form only as provided in the Financial Proposal Instructions and the Financial Proposal Form itself.

Issued and authorized by

<signed> Rachel J. Cruse Procurement Officer